Prof. Friedemann Paul MD

since 2016: Professor (W2), tenure professorship for Clinical and Experimental Neuroimmunology, Charité
2011 – 2016: Professor (W2), Neurology, NeuroCure Clinical Research Center, Charité
since 2010: Head, research group, Clinical and Experimental Neuroimmunology, Experimental and Clinical Research Center, Charité Campus Buch
since 2008: Head, research group, Clinical Neuroimmunology, NeuroCure Clinical Research Center, Charité
2004 – 2010: Resident and senior physician, Cecilie Vogt Clinic for Neurology, Charité
since 2003: Resident in Neurology
2002 – 2003: Training in Psychiatry, Schlosspark Klinik Berlin
2001 – 2004: Training in Epileptology and Electroencephalography, Epilepsiezentrum Berlin-Brandenburg
1996 – 2001: Training in Neurology und Clinical Neurophysiology, Auguste Viktoria Klinikum, Berlin
1988 – 1995: Medical studies at Freie Universität Berlin; Clinical training in France, Israel, and Zimbabwe

Research fields

  • Neuromyelitis optica (Devic’s Syndrome)
  • Neurodegeneration and Neuroprotection in Multiple Sclerosis (MS) and Experimental Autoimmune Encephalomyelitis (EAE)
  • Neurological Complications of Chronic Inflammatory Bowel Diseases Diagnostic Tools in Neuro-immunology (Imaging (OCT, MRI, Ultrasound), Laboratory, and CSF Biomarkers)
  • Association of structural damage and dysfunction of the visual system in autoimmune disorders of the Central Nervous System

Activities in the scientific community, honors, awards

since 2016: Medical Consultant for EU- Announcements for Research Programmes on Rare Diseases (E-RARE)
since 2015: Associate Editor “Neurology: Neuroimmunology and Neuroinflammation”
since 2014: Medical Consultant for Science Council (BfarM)
since 2013: Board member of the Competence Network Multiple Sclerosis (KKNMS)
since 2011: Member of the Guthy Jackson Foundation Clinical Consortium (www.guthyjacksonfoundation.org)
since 2011: Academic Editor, PLoS ONE
since 2009: Member, Editorial Board, EPMA Journal
since 2009: National representative, European Association for Predictive, Preventive and Personalised Medicine (EPMA)
since 2008: MS-Subkommittee der European Neurological Society (ENS)
since 2008: Co-initiator, NEMOS-Initiative, coordinator of the German Neuromyelitis optical study group (www.nemos-net.de)

Selected publications

Dinkin M, Paul F. Higher macular volume in patients with MS receiving fingolimod: positive outcome or side effect? Neurology. 2013; 80(2), 128-9.

Zimmermann H, Freing A, Kaufhold F, Gaede G, Bohn E, Bock M, Oberwahrenbrock T, Young KL, Dörr J, Wuerfel JT, Schippling S, Paul F, Brandt AU. Optic neuritis interferes with optical coherence tomography and magnetic resonance imaging correlations. Mult Scler. 2013; 19(4), 443-50.

Sinnecker T, Bozin I, Dörr J, Pfueller CF, Harms L, Niendorf T, Brandt AU, Paul F, Wuerfel J. Periventricular venous density in multiple sclerosis is inversely associated with T2 lesion count: a 7 Tesla MRI study.Mult Scler. 2013; 3, 316-25.

Wuerfel J, Sinnecker T, Ringelstein EB, Jarius S, Schwindt W, Niendorf T, Paul F, Kleffner I, Dörr J. Lesion morphology at 7 Tesla MRI differentiates Susac syndrome from multiple sclerosis. Mult Scler. 2012; 11,1592-9.

Sinnecker T, Dörr J, Pfueller CF, Harms L, Ruprecht K, Jarius S, Brück W, Niendorf T, Wuerfel J, Paul F. Distinct lesion morphology at 7-T MRI differentiates neuromyelitis optica from multiple sclerosis. Neurology. 2012; 79, 708-14.

Sinnecker T, Mittelstaedt P, Dörr J, Pfueller CF, Harms L, Niendorf T, Paul F, Wuerfel J. Multiple sclerosis lesions and irreversible brain tissue damage: a comparative ultrahigh-field strength magnetic resonance imaging study. Arch Neurol. 2012; 69(6), 739-45.

Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, Paul F, Aktas O; Neuromyelitis Optica Study Group. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol. 2012; 69(2), 239-45.

Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Bergh FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, Münch C, Winkelmann A, Zettl U UK, Metz I, Veauthier C, Sieb JP, Wilke C, Hartung HP, Aktas O, Paul F. J. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. Neuroinflammation. 2012; 9,14.

Brandt AU, Oberwahrenbrock T, Ringelstein M, Young KL, Tiede M, Hartung HP, Martin R, Aktas O and Paul F*. Schippling S*. Primary retinal pathology in multiple sclerosis as detected by optical coherence tomography. Brain 2011; 134, 1-3; e193 | * equal contribution

Bellmann-Strobl, J, Wuerfel, J, Aktas, O, Dorr, J, Wernecke, KD, Zipp, F and Paul, F. Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis. Neurology. 2009; 73, 1624-7.